USA flag logo/image

An Official Website of the United States Government

STTR PHASE I: Nano-Needle DNA Biosensor For Iin-Situ Direct Detection

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
88479
Program Year/Program:
2008 / STTR
Agency Tracking Number:
0740525
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NanoFacture, Inc.
16301 NE 8th St Ste 110 Bellevue, WA 98008
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: STTR PHASE I: Nano-Needle DNA Biosensor For Iin-Situ Direct Detection
Agency: NSF
Contract: 0740525
Award Amount: $64,996.00
 

Abstract:

This STTR Phase I research proposal will demonstrate the feasibility of a nanoscale needle (nano-needle) probe biosensor assaying low-abundance nucleic acids without target-/signal amplification. The unique point in the proposed work lies in the combined use of dielectrophoresis and capillary action to fabricate a high-aspect ratio nano-needle made of a hybrid nanomaterial and to operate the nano-needle as a biosensor, achieving high sensitivity through size-exclusive sample concentration. The company has already succeeded in nonspecifically sampling/assaying intercalator-treated lambda-DNA spiked into a buffer or cell solution in a quantitative manner. The sensitivity of this achievement was around 10pg/mL (0.3fM) which is comparable to the concentration of naturally occurring DNA species and sufficient for screening/detection of circulating DNA in blood (sub-50ng/mL). The method will pave the way to high throughput fabrication of high aspect ratio nano-needle structures and the application to the biosensing platform. The proposed nano-needle biosensor device will enable simple, rapid, yet sensitive detection without target-/signal amplification and minimize the operation in terms of the physical size, corresponding energy consumption, sample size, and sample preparation time as a field-deployable device. The biosensor is aimed for point-of-care-testing using minimally treated or raw samples. Eventually, the device will be applicable to nucleic acid testing (NAT) for rapid screening of diseases (e.g. cancer), which is enabled through minimally treated samples.

Principal Investigator:

Kyonghoon Lee
PhD
7342554311
hoonlee@nano-facture.com

Business Contact:

Kyonghoon Lee
PhD
7342554311
hoonlee@nano-facture.com
Small Business Information at Submission:

NanoFacture, Inc.
3983 Research Park Dr. Suite 100 Ann Arbor, MI 48108

EIN/Tax ID: 204416837
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
University of Washington
1100 NE 45th Street
Suite 300
Seattle, WA 98105
Contact: Kyonghoon Lee
Contact Phone: (206) 543-4043
RI Type: Nonprofit college or university